| ID Source | ID |
|---|---|
| PubMed CID | 4454085 |
| CHEMBL ID | 1312229 |
| CHEBI ID | 105083 |
| Synonym |
|---|
| EU-0057600 |
| MLS000101498 , |
| smr000017778 |
| CHEBI:105083 |
| AKOS000811084 |
| STK979421 |
| ethyl {1-[(9-methyl-4-oxo-4h-pyrido[1,2-a]thieno[2,3-d]pyrimidin-2-yl)carbonyl]-3-oxopiperazin-2-yl}acetate |
| HMS2246K04 |
| AKOS016148459 |
| bdbm43593 |
| cid_4454085 |
| CHEMBL1312229 |
| lsm-16446 |
| Q27182768 |
| SR-01000007446-1 |
| sr-01000007446 |
| ethyl 2-[1-(10-methyl-2-oxo-6-thia-1,8-diazatricyclo[7.4.0.03,7]trideca-3(7),4,8,10,12-pentaene-5-carbonyl)-3-oxopiperazin-2-yl]acetate |
| Z119980560 |
| Class | Description |
|---|---|
| pyridopyrimidine | Any organic heterobicyclic compound consisting of a pyridine ring ortho-fused at any position to a pyrimidine ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.1838 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 31.6228 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Nrf2 | Homo sapiens (human) | Potency | 35.4813 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 7.0795 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 35.4813 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 25.1189 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 33.5521 | 4.4668 | 18.3916 | 35.4813 | AID1467; AID2107 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 100.0000 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 32.9090 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2112; AID2242 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 112.2020 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| snurportin-1 | Homo sapiens (human) | Potency | 112.2020 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| relaxin receptor 1 isoform 1 | Homo sapiens (human) | Potency | 17.7828 | 0.0388 | 14.3501 | 43.6206 | AID2676 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 5.6234 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 39.8107 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| STAT3, partial | Homo sapiens (human) | IC50 (µMol) | 55.7000 | 0.0760 | 4.0758 | 8.6430 | AID1398 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| signal transducer and activator of transcription 1-alpha/beta isoform alpha | Homo sapiens (human) | EC50 (µMol) | 55.7000 | 0.4180 | 1.3618 | 2.9980 | AID1406 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||